Getinge Group Interim Report January-September 2013

Regulatory News:

Getinge Group (STO:GETIB):

Reporting period January – September

· Order intake rose by 3.9% to SEK 18,464 M (17,767), and grew organically by 3.3%

· Net sales increased by 6.7% to SEK 17,530 M (16,433), and grew organically by 5.7%

· Profit before tax declined by 27.4% to SEK 1,445 M (1,989)

· Net profit declined by 28.3% to SEK 1,055 M (1,472)

· Earnings per share declined by 28.5% to SEK 4.40 (6.15)

· EBITA before restructuring declined by 7.0% to 2,704 M (2,906). Adjusted for exchange-rate effects and the Medical Device Tax introduced in the US, EBITA rose by 4.6%

Reporting period July - September

· Orders received rose by 4.2% to SEK 5,981 M (5,742), and grew organically by 2.4%

· Net sales increased by 5.0% to SEK 5,850 M (5,574), and grew organically by 3.1%

· Profit before tax declined by 19.3% to SEK 568 M (704).

· EBITA before restructuring declined by 12.2% to SEK 907 M (1,033). Adjusted for exchange-rate effects and the Medical Device Tax introduced in the US, EBITA declined by 4.5%

· Strong cash flow during the quarter

· Getinge’s head office relocates to Gothenburg 2014

Third quarter 2013

The third quarter was disappointing in terms of earnings. The improvement in volume growth that was seen in both the order intake and invoicing did not have the impact on earnings that was forecast, primarily due to unfavourable market and product mix, in addition to the challenging exchange-rate scenario. The Group will intensify its ongoing work to realise the significant efficiency potential found within the Group.

Teleconference with CEO Johan Malmquist and CFO Ulf Grunander

15 October 2013 at 15:00 pm Swedish time

Sweden: +46 (0) 8 5033 6538

UK: +44 (0) 20 3427 1912

US: +1 212 444 0896

Code: 5099501

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.

This information was brought to you by Cision http://news.cision.com